Acquisitive US biotech Kriya Therapeutics yesterday revealed that it has acquired Tramontane Therapeutics, a private gene therapy company focused on developing treatments for metabolic and neurodegenerative diseases.
Tramontane, a spin out from Universitat Autònoma de Barcelona (UAB), is now a wholly-owned subsidiary of Kriya.
With the transaction, financial terms of which have not been disclosed, Kriya acquires a portfolio of fibroblast growth Factor 21 (FGF21) assets including Tramontane’s lead program, an adeno-associated virus (AAV) vector designed to express a steady level of the native FGF21 protein. FGF21 has beneficial metabolic effects across several target organs including the liver. Importantly, FGF21 has been established as a clinically-validated biological target in non-alcoholic steatohepatitis (NASH), which Kriya has prioritized as its lead FGF21 program.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze